Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
about
Genetic and nongenetic risk factors for childhood cancerCommon variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastomaIdentification of functional SNPs in BARD1 gene and in silico analysis of damaging SNPs: based on data procured from dbSNP databasePolymorphisms in the calcium-sensing receptor gene are associated with clinical outcome of neuroblastoma.Impact of interleukin-6 -174 G>C gene promoter polymorphism on neuroblastoma.HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.Neuroblastoma: developmental biology, cancer genomics and immunotherapy.The genetics of splicing in neuroblastoma.Candidate Gene Association Analysis of Neuroblastoma in Chinese Children Strengthens the Role of LMO1BARD1 mediates TGF-β signaling in pulmonary fibrosis.Expression of oncogenic BARD1 isoforms affects colon cancer progression and correlates with clinical outcome.Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma.Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon CancerReplication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibilityAntagonizing functions of BARD1 and its alternatively spliced variant BARD1δ in telomere stability.Children's Oncology Group's 2013 blueprint for research: neuroblastoma.Alternative splicing in cancer: implications for biology and therapy.Recent insights into the biology of neuroblastoma.Mechanisms of neuroblastoma regressionA LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.Genetic discoveries and treatment advances in neuroblastoma.The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma.Common genetic variants in NEFL influence gene expression and neuroblastoma risk.Genetic susceptibility to neuroblastoma.BARD1 serum autoantibodies for the detection of lung cancer.Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.Genome-wide pathway analysis in neuroblastoma.Dualistic Role of BARD1 in Cancer.Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.A cross-sectional study of associations between nonsynonymous mutations of the BARD1 gene and breast cancer in Han Chinese women.Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Non-Polyalanine Repeat Expansion Mutations.Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
P2860
Q27693894-0BCF8F87-0B36-43B2-96E9-1A94C70ECA6DQ28943271-8463985D-6458-45B0-B28A-450C4A841755Q30000832-05BE9BD4-ABC3-4890-B4EB-45A18F75CE7BQ34637949-EF54163A-41C3-47EA-A512-6F23F800A86DQ35034812-71FAFA10-CFC1-4B48-B2C3-475F5BEFB08BQ35070712-B8698AC7-52C1-40C2-AB57-62701A9A65BDQ35283020-9B72CD71-0E74-49CF-ABA6-B2D4F7E9F274Q35328703-877B8B64-3B78-45F4-BA52-22BC7409F223Q35648303-A9C51550-BE9C-4F15-852A-08BEE305D38AQ36105254-CD5189C9-D3A6-4B4A-8F59-C4E4834E0117Q36166792-A7702BEE-B504-4946-B733-67C88D08017AQ36381614-B9296735-C211-4340-A8F0-C8242462BC69Q36919195-2AE1DDF1-F226-4599-A7A6-9095C2F93F37Q37026820-A9CBE8FC-1916-4C9A-8517-ADFCD2FDA672Q37705964-E0F26416-4E8D-43A0-845D-FD03A299C0F1Q38068818-F44B0C4B-4E18-4D8B-B130-5085A4AFE045Q38179828-BD64F995-20E0-48ED-B509-4A36F711D74AQ38240010-83FAF4CD-0F7C-4ECE-AC11-96E1A0930982Q38261519-12670CFD-F846-4718-B3CC-BB67C4C907BEQ38295876-DC3B0B05-D943-46B8-9CBA-35FADC848F72Q38625880-17B7F1BA-97DE-4258-A1BB-0843BBCBD668Q38635551-6A138377-15A1-41B6-A6C2-5AEF149D845DQ38698465-8210A16A-EBD9-48A0-8527-1C27F69B50BCQ38948164-42042C87-9A0B-4E51-A260-8022BEC818BBQ39273903-D7F21366-67A0-4229-A841-58849C667D78Q41281453-EF1448C0-52A3-45D3-A820-D51BF9E29650Q42276835-BCCDD9AC-5D08-434D-B1E6-A75069CDE4ABQ44804727-92DCEA24-FE21-4057-965B-383934BFBFC0Q47177315-8C14CA89-9F05-441B-9947-003CBE9C7010Q47424716-D3E3A699-E9F6-4388-AC95-267A21BFC7BFQ47727739-3AC56F8B-AC57-4E4F-9628-FEF07AD28F43Q47936860-F0858B38-51FB-4804-AE6F-4DB06EC2FA3BQ48874456-A7C2AE04-F1A7-4FA2-84D4-2748AB960A93
P2860
Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@en
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@nl
type
label
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@en
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@nl
prefLabel
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@en
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@nl
P2093
P2860
P1433
P1476
Common variation at BARD1 resu ...... sceptibility and oncogenicity.
@en
P2093
Andrew C Wood
Bruce R Pawel
Cuiping Hou
Cynthia Winter
Edward F Attiyeh
Eric F Rappaport
Geoffrey Norris
Hakon Hakonarson
Irmgard Irminger-Finger
P2860
P304
P356
10.1158/0008-5472.CAN-11-3703
P407
P577
2012-02-20T00:00:00Z